December 5, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
December 3, 2024
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 2, 2024
Revolution Medicines Announces Commencement of Public Offering of Common Stock
December 2, 2024
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
November 27, 2024
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
November 6, 2024
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 5, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
October 30, 2024
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
October 25, 2024
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
October 23, 2024
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma